Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-7475-03: ONO-7475 in combination with osimertinib in EGFR-mutated NSCLC
jRCT2051210045Phase 1Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ONO-7475 in non-small cell lung cancer (NSCLC), sponsored by Ono Pharmaceutical. Primary endpoints: Tolerability and Safety. Started Aug 2021; status: completed.
02
Drugs
ONO-7475
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2051210045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210045.